Annual FCF
-$49.29 M
+$54.13 M+52.34%
31 December 2023
Summary:
Xeris Biopharma Holdings annual free cash flow is currently -$49.29 million, with the most recent change of +$54.13 million (+52.34%) on 31 December 2023. During the last 3 years, it has risen by +$31.65 million (+39.10%). XERS annual FCF is now -205.71% below its all-time high of -$16.12 million, reached on 31 December 2016.XERS Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly FCF
-$8.39 M
+$2.35 M+21.90%
30 September 2024
Summary:
Xeris Biopharma Holdings quarterly free cash flow is currently -$8.39 million, with the most recent change of +$2.35 million (+21.90%) on 30 September 2024. Over the past year, it has increased by +$6.56 million (+43.88%). XERS quarterly FCF is now -214.35% below its all-time high of $7.34 million, reached on 31 December 2023.XERS Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM FCF
-$32.27 M
+$6.56 M+16.90%
30 September 2024
Summary:
Xeris Biopharma Holdings TTM free cash flow is currently -$32.27 million, with the most recent change of +$6.56 million (+16.90%) on 30 September 2024. Over the past year, it has increased by +$40.61 million (+55.73%). XERS TTM FCF is now -735.66% below its all-time high of -$3.86 million, reached on 31 March 2017.XERS TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
XERS Free Cash Flow Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +52.3% | +43.9% | +55.7% |
| 3 y3 years | +39.1% | +63.4% | +59.0% |
| 5 y5 years | +14.7% | +72.9% | +65.8% |
XERS Free Cash Flow High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +52.3% | -214.3% | +82.7% | at high | +73.4% |
| 5 y | 5 years | at high | +53.3% | -214.3% | +82.7% | at high | +73.4% |
| alltime | all time | -205.7% | +53.3% | -214.3% | +82.7% | -735.7% | +73.4% |
Xeris Biopharma Holdings Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$8.39 M(-21.9%) | -$32.27 M(-16.9%) |
| June 2024 | - | -$10.74 M(-47.5%) | -$38.83 M(-10.5%) |
| Mar 2024 | - | -$20.47 M(-378.9%) | -$43.38 M(-12.0%) |
| Dec 2023 | -$49.29 M(-52.3%) | $7.34 M(-149.1%) | -$49.29 M(-32.4%) |
| Sept 2023 | - | -$14.96 M(-2.2%) | -$72.88 M(-3.9%) |
| June 2023 | - | -$15.29 M(-42.0%) | -$75.85 M(-6.8%) |
| Mar 2023 | - | -$26.38 M(+62.3%) | -$81.38 M(-21.3%) |
| Dec 2022 | -$103.42 M(+7.0%) | -$16.25 M(-9.4%) | -$103.42 M(-11.0%) |
| Sept 2022 | - | -$17.93 M(-13.9%) | -$116.24 M(-4.1%) |
| June 2022 | - | -$20.82 M(-57.0%) | -$121.23 M(+0.5%) |
| Mar 2022 | - | -$48.41 M(+66.5%) | -$120.64 M(+24.9%) |
| Dec 2021 | -$96.62 M(+19.4%) | -$29.08 M(+26.9%) | -$96.62 M(+22.9%) |
| Sept 2021 | - | -$22.92 M(+13.2%) | -$78.64 M(+8.2%) |
| June 2021 | - | -$20.24 M(-17.0%) | -$72.68 M(-4.8%) |
| Mar 2021 | - | -$24.39 M(+119.8%) | -$76.35 M(-5.7%) |
| Dec 2020 | -$80.94 M | -$11.09 M(-34.6%) | -$80.94 M(-18.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2020 | - | -$16.96 M(-29.0%) | -$99.66 M(-12.3%) |
| June 2020 | - | -$23.91 M(-17.5%) | -$113.64 M(+0.5%) |
| Mar 2020 | - | -$28.97 M(-2.8%) | -$113.07 M(+7.2%) |
| Dec 2019 | -$105.45 M(+82.5%) | -$29.82 M(-3.7%) | -$105.45 M(+11.9%) |
| Sept 2019 | - | -$30.95 M(+32.7%) | -$94.22 M(+17.8%) |
| June 2019 | - | -$23.33 M(+9.3%) | -$79.96 M(+12.6%) |
| Mar 2019 | - | -$21.35 M(+14.9%) | -$71.00 M(+22.9%) |
| Dec 2018 | -$57.79 M(+127.8%) | -$18.59 M(+11.4%) | -$57.79 M(+19.1%) |
| Sept 2018 | - | -$16.69 M(+16.1%) | -$48.54 M(+29.6%) |
| June 2018 | - | -$14.38 M(+76.7%) | -$37.45 M(+26.4%) |
| Mar 2018 | - | -$8.14 M(-12.8%) | -$29.64 M(+16.9%) |
| Dec 2017 | -$25.36 M(+57.3%) | -$9.34 M(+66.7%) | -$25.36 M(+58.3%) |
| Sept 2017 | - | -$5.60 M(-14.7%) | -$16.03 M(+53.7%) |
| June 2017 | - | -$6.56 M(+70.0%) | -$10.43 M(+170.0%) |
| Mar 2017 | - | -$3.86 M | -$3.86 M |
| Dec 2016 | -$16.12 M | - | - |
FAQ
- What is Xeris Biopharma Holdings annual free cash flow?
- What is the all time high annual FCF for Xeris Biopharma Holdings?
- What is Xeris Biopharma Holdings annual FCF year-on-year change?
- What is Xeris Biopharma Holdings quarterly free cash flow?
- What is the all time high quarterly FCF for Xeris Biopharma Holdings?
- What is Xeris Biopharma Holdings quarterly FCF year-on-year change?
- What is Xeris Biopharma Holdings TTM free cash flow?
- What is the all time high TTM FCF for Xeris Biopharma Holdings?
- What is Xeris Biopharma Holdings TTM FCF year-on-year change?
What is Xeris Biopharma Holdings annual free cash flow?
The current annual FCF of XERS is -$49.29 M
What is the all time high annual FCF for Xeris Biopharma Holdings?
Xeris Biopharma Holdings all-time high annual free cash flow is -$16.12 M
What is Xeris Biopharma Holdings annual FCF year-on-year change?
Over the past year, XERS annual free cash flow has changed by +$54.13 M (+52.34%)
What is Xeris Biopharma Holdings quarterly free cash flow?
The current quarterly FCF of XERS is -$8.39 M
What is the all time high quarterly FCF for Xeris Biopharma Holdings?
Xeris Biopharma Holdings all-time high quarterly free cash flow is $7.34 M
What is Xeris Biopharma Holdings quarterly FCF year-on-year change?
Over the past year, XERS quarterly free cash flow has changed by +$6.56 M (+43.88%)
What is Xeris Biopharma Holdings TTM free cash flow?
The current TTM FCF of XERS is -$32.27 M
What is the all time high TTM FCF for Xeris Biopharma Holdings?
Xeris Biopharma Holdings all-time high TTM free cash flow is -$3.86 M
What is Xeris Biopharma Holdings TTM FCF year-on-year change?
Over the past year, XERS TTM free cash flow has changed by +$40.61 M (+55.73%)